AzTrials
AzTrials

Cardiac SurgeryCardiOGlcNAcNCT06754709

Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children

An observational study of Cardiac Surgery and Extracorporeal Circulation; Complications, run by Nantes University Hospital at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cardiac surgery requires the use of extracorporeal circulation (ECC). Age-related differences in inflammatory response, the greater susceptibility of immature organ systems to injury and the larger ratio of extracorporeal circuitry to patient size make younger and smaller patients more vulnerable to organ injury. Read more about this study

Who is it for?
Ages Up to 17 years
How many people
300 participants
Where
1 siteFrance
Study dates
13 Feb 2025to 31 Jan 2035
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Children aged between 0 and 17 undergoing cardiac surgery with extracorporeal circulation

Who may be able to join

  • Age from 0 to 17 years at the time of sampling
  • Children undergoing CEC for cardiac surgery
  • Signed bio-collection consent

Who cannot join

  • Children with an infection
  • Children with fever
  • Children with an immune deficiency
  • Children with autoimmune disease
  • Children with metabolic disease
  • Children with haematological diseases
Show all 9Show fewer
  • Children with a genetic disease
  • Unsigned consent
  • Refusal by parents or child

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Nantes University Hospital

    Nantes

    Manon Denis, +33 2 40 08 34 83, manon.denis-med@chu-nantes.fr

    Recruiting

Other trials in France

About this study

Official title: Evaluation of the Levels of O-GlcNAcylation of Cardiac and Blood Proteins in Paediatric Cardiac Surgery and Identification of Therapeutic Targets

Cardiac surgery requires the use of extracorporeal circulation (ECC). Age-related differences in inflammatory response, the greater susceptibility of immature organ systems to injury and the larger ratio of extracorporeal circuitry to patient size make younger and smaller patients more vulnerable to organ injury. The main problem associated with ECC in neonates and infants is the duration of ECC due to heavier surgeries leading to a prolonged inflammatory state resulting in capillary leak syndrome, low cardiac output syndrome and organ dysfunction, resulting in higher morbidity and mortality. The means of limiting this inflammatory response remain limited. Future studies should aim to address new post-ECC prophylactic targets to improve myocardial and endothelial function. Cardiac metabolism is an important area of research because it plays a central role in maintaining cardiac function under stress. The study of O-GlcNAcylation could therefore be an interesting therapeutic target, given the beneficial role of its stimulation in acute stress situations, as demonstrated in sepsis.

Read the detailed description

Extracorporeal circulation (ECC) is a circuit that provides circulatory assistance to facilitate surgical access to a bloodless and, in some cases (in the case of cardioplegia) immobile operating field. This strategy has led to technical and procedural advances in cardiothoracic surgery that would have been unthinkable without bypass surgery. ECC leads to systemic inflammatory response syndrome and is associated with postoperative complications, including myocardial dysfunction, respiratory failure, acute renal failure, neurological dysfunction, coagulation disorders and, finally, multivisceral failure. Numerous data suggest that inflammation and oxidative stress occur shortly after the start of bypass surgery and progress over time. ECC-induced SIRS, similar to sepsis, leads to stimulation and activation of endothelial cells. Circulating pro-inflammatory cytokines can also directly stimulate endothelial cells, resulting in a pathological increase in permeability leading to the development of capillary leak syndrome, causing tissue oedema and impaired oxygen utilisation leading to multiple organ dysfunctions. Clinical practice has shown that the majority of infants suffer haemodynamic failure within 4 to 8 hours of the operation. This failure could be related to a state of vasodilatation (capillary leakage) and/or a low cardiac output syndrome. The timing of the onset of this failure correlates with peak cytokine secretion. The risk factors for severe SIRS in paediatric cardiac surgery are low weight, heart disease with an intra-cardiac right-left shunt, the duration of aortic clamping and the length of the bypass operation. This state of vasoplegia is associated with an increase in lactate production, reflecting an imbalance between organ oxygen demand and supply, an increase in amine requirements and an increase in invasive ventilation time. In many cases, vasoplegia is associated with low cardiac output syndrome. This syndrome is the most common post-operative complication in paediatric cardiac surgery. Twenty-five to sixty per cent of newborns develop low cardiac output syndrome (LCOS) in the 6 to 18 hours following surgery, with mortality occurring in 20% of cases. Current means of limiting post-CEC SIRS remain limited. The understanding of inflammatory processes and the interaction between humoral factors and the cellular immune response has progressed rapidly over the last decade. Multiple anti-inflammatory strategies have been applied in the past, significantly reducing cytokine levels without improving clinical outcome. This means that the amplitude of inflammatory cytokine secretion does not directly predict patient outcome. Future studies should aim to address new post-CEC prophylactic targets to improve myocardial and endothelial function. Cardiac metabolism is an important area of research because it plays a central role in maintaining cardiac function under stress. In recent years, there has been considerable interest in O-GlcNAcylation, a post-translational modification of proteins, as it plays a key role in regulating cellular metabolism and the ability to adapt to stress and cell survival. O-N-acetyl glucosaminylation, more simply known as O-GlcNAcylation, is a ubiquitous, rapid and reversible post-translational modification involving the addition of a monosaccharide: ß-D-N-acetylglucosamine to the serine and threonine residues of proteins. In physiological conditions, some of the glucose entering the cell is directed towards the hexosamine biosynthesis pathway (VBH), which leads to the production of UDP-GlcNAc, used by O-GlcNAc transferase (OGT) to O-GlcNAcylate proteins. The reverse reaction is catalysed by O-GlcNAcase (OGA). VBH is at the crossroads of several cellular metabolic pathways (glucose, acetyl-CoA, glutamine, uridine and ATP) and O-GlcNAcylation is considered to be a metabolic sensor. The number of O-GlcNAcylated targets (+3000 proteins) bears witness to the involvement of this modification in various cellular functions. O-GlcNAc levels are finely modulated according to the cell's metabolic environment, enabling it to adapt to stress. This last point is particularly important as metabolism changes during development and during CEC, which impacts the hexosamine biosynthesis pathway and therefore O-GlcNAcylation. O-GlcNAcylation is particularly difficult to study at cardiac level, but the investigators have shown that there is a close correlation between blood (whole blood) and cardiac O-GlcNAc levels in rats. Preliminary data in rats have shown that O-GlcNAcylation levels decrease during bypass surgery and that there is an interest in increasing O-GlcNAcylation levels during bypass surgery in order to reduce organ failure, but no human data have been published in this context.

Keywords
cardiac surgery, extracorporeal circulation, metabolism, low cardiac output, O-GlcNAcylation,, systemic inflammatory response syndrome
Medical subject headings
Cardiac Output, Low, Systemic Inflammatory Response Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06754709
Study groupRoleWhat they receive
Cardiac surgery with extracorporeal circulationChildren aged between 0 and 17 undergoing cardiac surgery with extracorporeal circulation. The children will have blood samples taken at the same time as the samples already taken for all the children as part of the intra- and post-operative management of cardiac surgery. If necessary, the resection of cardiac tissue planned for cardiac surgery will be preserved for the study. Patients' administrative data will be collected at the time of sampling and anonymised. Medical data will be collected retrospectively from the medical record. Patients will be monitored as part of the post-operative cardiac surgery network and data will be collected retrospectively from the patient's file. Western blot analysis (measurement of O-GlcNAcylation) will be carried out as soon as a sufficient number of samples are available in the bio-collection (generally by 15 samples)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of O-GlcNAcylation levels in cardiac surgery in children

    To evaluate the evolution of O-GlcNAcylation levels in pre-per-post extracorporeal circulation in children

    Measured: From start of the surgery to 12 hours after start of the surgery

Secondary outcomes (1)
  1. Analysis of a potential link between O-GlcNAcylation levels and the prognosis of patients after cardiac surgery

    To study the correlation between blood and cardiac O-GlcNAcylation levels and patient prognosis

    Measured: Up to 6 years after inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jan 2025
  2. Study start13 Feb 2025
  3. Primary completion31 Jan 2034 (estimated)
  4. Study completion31 Jan 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06754709
Sponsor's protocol ID
RC24_0572
Acronym
CardiOGlcNAc
Status last verified
Apr 2025
First submitted
23 Dec 2024
Last updated
13 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Surgery and Extracorporeal Circulation; Complications, run by Nantes University Hospital at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Manon Denis (+33 2 40 08 34 83, manon.denis-med@chu-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of O-GlcNAcylation levels in cardiac surgery in children (time frame: From start of the surgery to 12 hours after start of the surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in